Evidence map›Paper›PMID 25254154›Full record

ArticleWorm2014

SUMO as a nuclear hormone receptor effector: New insights into combinatorial transcriptional regulation.

Jordan D Ward, Keith R Yamamoto, Masako Asahina

Abstract read
In one paragraph

Article in Worm, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The Binding Landscape of an Essential Nuclear Hormone Receptor inbioRxiv : the preprint server for biology · 2025
    Article
  2. The role of SUMOylation during development.Biochemical Society transactions · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jordan D WardDepartment of Cellular and Molecular Pharmacology; University of California; San Francisco, CA USA.
Keith R YamamotoDepartment of Cellular and Molecular Pharmacology; University of California; San Francisco, CA USA.
Masako AsahinaDepartment of Cellular and Molecular Pharmacology; University of California; San Francisco, CA USA ; Institute of Parasitology; Biology Centre ASCR; Ceske Budejovice, Czech Republic ; University of South Bohemia; Ceske Budejovice, Czech Republic.

Funding

GENE REGULATION BY STEROID RECEPTOR PROTEINSR01CA020535 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YAMAMOTO, KEITH ROBERT · 1985 to 2018
$8.9M
GENE REGULATION BY STEROID RECEPTOR PROTEINSR37CA020535 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI YAMAMOTO, KEITH ROBERT · 1990 to 1998
–
NCI NIH HHS R01 CA020535NCI NIH HHS R37 CA020535
6 · The paper itself

Abstract

Animal development is driven by robust, cell-specific gene expression programs. Understanding mechanistically how a single transcription factor (TF) can govern distinct programs with exquisite precision is a major challenge. We view TFs as signal integrators, taking information from co-regulator interactions, post-translational modifications, other transcription factors, chromatin state, DNA sequence and in some cases, specific noncovalent ligands, to determine the collection of genes regulated by a TF at any given time. Here, we describe a reductionist approach to combinatorial transcriptional regulation, focusing on a single C. elegans TF, the nuclear hormone receptor NHR-25, and a single post-translational modification, SUMO. We suggest that the ratio of sumoylated to unsumoylated NHR-25 could specify a switch-like cell-fate decision during vulval development. Direct examination of this "SUMO ratio" in vivo is challenging and we discuss possible solutions going forward. We also consider how sumoylation of multiple substrates might be coordinated during vulval development. Finally, we note that iteration of this approach could leverage our sumoylation findings to define the roles of other effectors of NHR-25 in the developing vulva and in other tissues.

Indexed as

C. eleganscell fategene expressionNHR-25nuclear hormone receptorsignalingSMO-1sumoylationtranscriptionvulva development

Identifiers

PMID25254154
PMCPMC4165532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.